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Objective To find a possible relation between the dynamics of antibiotic resistance of
Helicobacter pylori isolates and the consumption of antibiotics during the last several years
in Estonia.
Methods Helicobacter pylori isolates were collected from the gastric mucosa of patients
with peptic ulcer (153) and gastritis (68) and isolated on the Columbia Agar Base. From
1995 to 1997 the disk-diffusion method was used for testing of H. pylori susceptibility to
metronidazole (115 isolates), erythromycin (119 isolates), tetracycline (119 isolates) and
amoxicillin (119 isolates). From 1998 to 2000 the susceptibility of H. pylori to metroni-
dazole (106 isolates), amoxicillin (30 isolates), clarithromycin (106 isolates) and cipro-
floxacin (30 isolates) was assessed by E tests. Data from the Estonian State Agency of
Medicines were used to determine the antibiotic consumption rate.
Results Up to the year 2000 all the investigated H. pylori isolates were susceptible to
ciprofloxacin; the resistance to clarithromycin, tetracycline, amoxicillin and erythromycin
was 3%, 1.7%, 0.7% and 2.5%, respectively. Forty-six percent of H. pylori isolates were
resistant to metronidazole. During 1995–2000 the consumption of amoxicillin, erythro-
mycin and ciprofloxacin increased and the consumption of tetracycline decreased. The
increasing consumption of amoxicillin reached a level 5.7 times than that of the consistent
use of metronidazole. The resistance to amoxicillin appeared to be very low and
resistance to metronidazole was continuously high. The increase of clarithromycin
consumption (from 0.002 to 1.119 defined daily doses/1000) during three years was
associated with the appearance of the first clarithromycin-resistant isolates in 2000.
Conclusion No relation was observed between the antibiotic consumption rate and the
resistance pattern of H. pylori to metronidazole, amoxicillin, erythromycin, tetracycline
and ciprofloxacin during recent years among the in population.
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I N T R O D U C T I O N
Helicobacter pylori is found colonizing the stomach
of patients with chronic gastritis and peptic ulcer
disease [1,2]. Eradication of H. pylori has a signifi-
cant effect on the clinical symptoms and cure rate
of peptic ulcer [3]. However, resistance of H. pylori
to antibiotics can be a cause of treatment failures
[4].
A significant difference in the resistance to anti-
biotics, especially to metronidazole and clarithro-
mycin, has been found among countries. The
resistance to metronidazole usually ranges from 10
to 90% [5,6]. The clarithromycin-resistance rate in
Europe varies from 0 to 15% [5,6]. The prevalence
of resistance to erythromycin, tetracycline and
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amoxicillin is universally very low in Europe [5,7],
but cross-mutations conferring resistance to
macrolides may exist [8,9]. Data concerning resis-
tance of H. pylori to fluoroquinolones are scarce.
There is general agreement that increasing anti-
microbial resistance is related to the selective pres-
sure exerted by the use of antibiotics [10]. A higher
rate of metronidazole resistance of H. pylori has
been associated with the extensive use of this
inexpensive antibiotic for the treatment of para-
sitic, genital and dental infections [11]. On the
other hand, clarithromycin resistance mainly
depends on the intensity of administration of
the newly introduced medicine in different coun-
tries. In those countries where clarithromycin is
widely used for the treatment of respiratory tract
infections, the resistance of H. pylori isolates is
higher than in those where macrolides are rarely
used [5,7,11]. In Estonia the population was not
treated with clarithromycin before 1997, when
clarithromycin was officially registered. This
may offer a good opportunity to estimate the
development of H. pylori resistance.
In other studies, metronidazole- and amoxicil-
lin-resistance rates have remained stable, but clar-
ithromycin-resistant isolates have increased in
patients treated with these antibiotics [12]. No data
comparing the resistance of H. pylori to different
antimicrobial agents with the dynamics of anti-
biotic consumption in the population are available.
The first objective of our study was to assess the
prevalence of metronidazole-, clarithromycin-,
erythromycin-, tetracycline-, amoxicillin- and
ciprofloxacin-resistant isolates of H. pylori in Esto-
nia from 1995 to 2000. The second goal was to find
the possible relation between the susceptibility
pattern of H. pylori and the rate of antibiotic use
during different years.
M E T H O D S
A total of 221 H. pylori isolates were obtained for
estimating an antibiotic susceptibility pattern over
a period of 6 years (from 25 April 1995 to 18
October 2001) from H. pylori-positive adult out-
patients (130 men and 91 women), all referred to
the Tartu University Outpatients Clinic for upper
gastrointestinal endoscopies. None of the patients
had a previous history of H. pylori infection.
Upper endoscopies were performed by the gas-
troscope Olympus-GIF 21. Biopsies were obtained
with medium-size forceps. Gastric ulcer was diag-
nosed if the ulcer was located at the angulus or
above it. Duodenal ulcer was diagnosed if the
ulcer was found in the praepyloric, pyloric, or
duodenal bulb area. The resulting endoscopic
diagnoses were the following: 153 cases of peptic
ulcer (duodenal or gastric ulcer) and 68 cases of
normal findings where gastritis was diagnosed
histologically according to the Sydney classifica-
tion [13].
The biopsy samples from the antrum and the
corpus were placed into the Stuart Transport Med-
ium and taken to the laboratory within 2 h.
Data from the Estonian State Agency of Medi-
cines were used to assess the antibiotic consump-
tion rate in the population [as defined daily doses
(DDD)/1000/annually]. To estimate the differ-
ences in dynamics of antibiotic consumption, the
data were divided into two periods (from 1995 to
1997 and from 1998 to 2000).
H. pylori was isolated on the Columbia Agar
Base supplemented with 7% horse blood and 1%
Isovitalex. The plates were incubated for 3–4 days
at 37 8C under microaerophilic conditions (Cam-
pyGen Oxoid) and Gram staining, oxidase, cata-
lase and urease reactions were used for H. pylori
identification.
From each patient, one H. pylori isolate was
tested for susceptibility to metronidazole, amox-
icillin, tetracycline, erythromycin, clarithromycin
and ciprofloxacin. A suspension was prepared in
Brucella broth (2 mL) equivalent to the McFarland
turbidity standard 3–4. From this suspension,
100 mL was transferred onto the surface of the
Columbia Agar Base with 7% horse blood and
1% Isovitalex and streaked with a cotton swab.
Antibiotic disks (BBL, Cockeysville, MD, USA) or
strips (the E test; AB Biodisk, Salna, Stockholm,
Sweden) were applied onto the surface of inocu-
lated and dried agar plates. For testing antibiotic
susceptibility, the plates were incubated in a
microaerophilic milieu at 37 8C for 3–4 days before
examination [6,14].
From 1995 to 1997, the disk-diffusion method
was used for H. pylori susceptibility testing to
metronidazole (115 isolates), erythromycin, tetra-
cycline and amoxicillin (119 isolates for each). The
following inhibition zones were regarded as indi-
cating antibiotic sensitivity of the H. pylori isolates:
>15 mm for metronidazole (5 mg), 23 mm for
erythromycin (15 mg), 19 mm for tetracycline
(30 mg) and 17 mm for amoxicillin (30 mg) [7,15].
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From 1998 to 2000 the susceptibility of H. pylori
to metronidazole (106 isolates), amoxicillin (30
isolates), clarithromycin (106 isolates) and cipro-
floxacin (30 isolates) was estimated by E tests. Anti-
biotic breakpoints employed for the E test were
8.0 mg/L for metronidazole,2.0 mg/L for clari-
thromycin and 8.0 mg/L for amoxicillin [4,7].
The random 30 H. pylori isolates from 30 patients
(10 with gastritis and 20 with peptic ulcer) were
tested for metronidazole susceptibility by the disk-
diffusion method and the E test, comparatively.
H. pylori strain ATCC 43504 was used as a
reference strain for quality control of antibiotic
susceptibility testing.
Data were analysed using a Jandel SigmaStat 2.0
program, using w2 or Fisher Exact Tests.
R E S U L T S A N D D I S C U S S I O N
The consumption rates of some antibiotics in Esto-
nia during 1995–2000, divided into two 3-year
periods are presented in Table 1. No change was
found in the consumption of metronidazole. The
consumption increased 2.4-fold for ciprofloxacin,
2.5-fold for amoxicillin, 1.3-fold for erythromycin
and decreased twofold for tetracycline. The use of
clarithromycin, a relatively new medicine in Esto-
nia (available since 1997) increased from 0 to 1.19
(DDD/1000). Amoxicillin was the most frequently
used antibiotic in 2000. The use of amoxicillin was
5.7-fold higher than that of metronidazole.
Metronidazole-sensitive and -resistant H. pylori
isolates were recovered in similar proportions: 120
H. pylori isolates were metronidazole-sensitive (69
by disk diffusion and 51 by the E test) and 101 were
metronidazole-resistant (46 isolates by disk diffu-
sion and 55 by the E test). The resistance to metro-
nidazole of H. pylori was 46% (40% by the disk-
diffusion method and 52% by the E test). The
differences between both methods were not sta-
tistically significant (P> 0.05).
There were no differences in metronidazole
susceptibility of isolates collected from patients
with peptic ulcer as compared to those who had
only gastritis (data not shown, P> 0.05).
From 106 investigated H. pylori isolates 103 were
sensitive to clarithromycin [minimum inhibitory
concentration (MIC) ranges from <0.016 to 2 mg/
L) and only three were resistant (MIC ranges from
6 to >256 mg/L), the resistance rate being 3%.
Among 119 isolates of H. pylori the resistance to
tetracycline (two isolates; 1.7%) and erythromycin
(three isolates; 2.5%) was low. The resistance to
amoxicillin (119 isolates tested by disk-diffusion
method and 30 by the E test) remained at 0.7% (one
isolate). The one isolate, resistant to erythromycin
was simultaneously resistant to tetracycline and
amoxicillin and the other isolate was resistant to
both erythromycin and tetracycline. All 30 H.
pylori isolates investigated were susceptible to
ciprofloxacin.
In 26 isolates (13 resistant and 13 sensitive),
equal values were obtained with both methods,
four isolates showed a different susceptibility pat-
tern and the discrepancy between both tests was
only 13.3%. In one case one isolate was sensitive
according to the E test and resistant according to
the disk-diffusion method. In three cases the iso-
lates resistant according to the E test were sensitive
to metronidazole according to the disk-diffusion
method.
The results of susceptibility tests performed in
different years are depicted in Table 2. No statis-
tically significant differences were found between
the resistance rates of H. pylori for the two different
3-year periods or by utilizing the different suscept-
ibility methods. The use of metronidazole and H.
Table 1 The differences in the consumption of some antibiotics (DDD/1000a) from 1995 to 1997 and from 1998 to 2000 in
Estonia
DDD/1000a
Consumption
Antibiotic 1995–1997 1998–2000 dynamics
Metronidazole 0.96 (0.83–1.29) 0.85 (0.80–0.86) Decrease 1.1-fold
Amoxicillin 1.38 (0.74–2.3) 3.49 (2.80–4.90) Increase 2.53-fold
Erythromycin 0.98 (0.94–1.03) 1.29 (1.50–1.44) Increase 1.32-fold
Tetracycline 1.14 (1.10–0.76) 0.42 (0.57–0.35) Decrease 2.7-fold
Ciprofloxacin 0.13 (0.10–0.16) 0.31 (0.27–0.3) Increase 2.38-fold
Clarithromycin 0.002b 1.11 (0.05–1.19) Increase from 0 to 1.19
aDDD/1000, defined daily doses per 1000 annually; bofficially registered in 1997.
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pylori-resistance patterns was quite stable, as no
statistically significant differences (P> 0.05) were
found (Figure 1). Even though the consumption of
amoxicillin increased 2.5-fold, the resistance to this
antibiotic remained very low. Nor could the com-
paratively low consumption of metronidazole be
associated with the highest (46%) resistance to
metronidazole, discovered by different suscept-
ibility testing methods in the microaerophilic
environment. In comparison with the use of metro-
nidazole and amoxicillin, the latter was much
higher. However, the resistance to metronidazole
was continuously high and the resistance to amox-
icillin was very low.
The goal of the study was to estimate the sus-
ceptibility of Estonian H. pylori isolates to different
antibiotics used in the treatment of H. pylori infec-
tions. The changes in the consumption rate of some
antimicrobial agents over a 6-year period were not
followed by an increase in antibiotic resistance of
H. pylori to these drugs. This was not the antici-
pated result; we expected that the increase or
decrease of antibiotic consumption would influ-
ence the microbial resistance pattern generally.
The extensive use of antibiotics usually leads to
an increase of resistance against these drugs. The
relation between the use of erythromycin and the
resistance of Streptococcus pyogenes to this antibio-
tic has already been verified [16].
Our particular interests were metronidazole, as
a medicine, used world-wide for a long period, the
macrolides, belonging to the treatment regimens
of a wide spectrum of infections for approximately
50 years, and the extensively consumed beta-lac-
tame antibiotics (amoxicillin). The resistance rate
of H. pylori to these antibiotics shows wide varia-
tion in different countries [7,11].
Thanks to the database of the Estonian State
Agency of Medicines, it was possible to acquire
6-year comparative data for the total consumption
of the antibiotics most frequently used in the
treatment regimens for H. pylori infection. The
dynamics of consumption of these antibiotics
was different: the use of metronidazole and ery-
thromycin was quite stable, but the use of clari-
thromycin increased from zero to 0.19 DDD/1000,
use of amoxicillin increased 2.4-fold, use of cipro-
floxacin increased 2.5-fold and tetracycline use
decreased 2.7-fold. Clarithromycin resistance
was not detected among H. pylori isolates in the
Estonian population from 1997 to 1999, and clar-
ithromycin seemed to be an excellent component
of the triple therapy used in the eradication of H.
pylori up to 2000 when the first resistant isolates
Table 2 Resistance of Helicobacter pylori isolates to antibiotics in Estonia during the last 6 years from (from 25 April 1995 to
31 December 1997 and from 1 January 1998 to 18 October 2000)
1995–1997 1998–2000
Antibiotic n Res. (%) n Res. (%)
Metronidazolea,b 115 40.0 106 52.0
Amoxicillina,b 99 1.0 50 0
Erythromycina 99 3.0 20 0
Tetracyclinea 99 2.0 20 0
Ciprofloxacinb 0 ndc 30 0
Clarithromycinb 16 0 90 3.33d
n, number of isolates; Res. (%), percent resistance.
aKirby–Bauer disk-diffusion method; bthe E test; cnot done; dall the clarithromycin-resistant isolates were collected in 2000.
Figure 1 The resistance to antibiotics (%) of Helicobacter
pylori in comparison with the use rate (DDD/1000).
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appeared. In comparing the use of metronidazole
and amoxicillin, the latter was used at a rate 5.7
times higher. However, the resistance to metroni-
dazole was continuously high and the resistance to
amoxicillin remained very low. At the same time,
the prevalence of resistance to amoxicillin, ery-
thromycin, tetracycline and ciprofloxacin was very
low or completely absent.
Likewise, there is a discrepancy between the
resistance and consumption of metronidazole.
Although the consumption of metronidazole
was lower than that of amoxicillin or ciproflocacin,
the resistance pattern was constantly high for
6 consecutive years. In the present study in the
year 2000, metronidazole resistance was 50% (gen-
erally 46%). The Norwegian metronidazole-resis-
tance rate was similar to that established by our
data [17] although the consumption was nearly 180
times lower (DDD/1000 was 0.0056). It is possible
that at continuously stable and quite low (1.0
DDD/1000) rate of consumption of metronidazole,
the high resistance pattern (46%) of H. pylori can be
largely attributed to the methodical problems of
sensitivity testing in microaerophilic vs. anaerobic
milieu [18,19].
At the beginning of our study, we had to use the
disk-diffusion method only; later E tests were
applied. The susceptibility pattern of H. pylori,
assessedbytheKirby–Bauerdisk-diffusionmethod,
and the E test showed only 13.3% discordance:
three isolates, resistant according to the E test were
sensitive to metronidazole according to the disk-
diffusion method. The reason for this pheno-
menon may be that the gradient profile around
the disk changes over time and a large inhibition
zone may in some cases reflect slower growth
[20]. These results confirm that the E test is more
reliable for studying the resistance of H. pylori
than the disk-diffusion method in the case of
single isolates. In contrast, if we compared the
average resistance to metronidazole of numerous
isolates, as assessed either by the disk-diffusion
method or by the E tests in different years, no
statistically significant changes were found. So the
results of the disk-diffusion tests are acceptable to
estimate H. pylori resistance in the population
generally.
We did not find any differences in metronida-
zole susceptibility of the H. pylori strains isolated
from patients with gastritis compared to those
from patients with peptic ulcer disease. Our data,
which show no significant correlation between the
patients’ diagnoses and the resistance patternsa-
pos; are in agreement with the results obtained by
other authors, showing that the patients with gas-
tritis and peptic ulcer can be colonized both with
resistant and sensitive H. pylori isolates [4].
To summarize, we did not observe a relation
between the changes in antibiotic consumption
(DDD/1000) rate and the resistance pattern of
H. pylori to amoxicillin, erythromycin, tetracycline
and ciprofloxacin during a 6-year follow-up per-
iod. The first clarithromycin-resistant isolates
appeared in 2000. Therefore, the consumption rate
of antibiotics in the Estonian population was not
directly associated with the antibiotic-resistance
profile of H. pylori during the past 6 years.
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